GSK, XenoPort revise Horizant pact

Just a few days after the FDA accepted GlaxoSmithKline's ($GSK) response to its complete response letter on Horizant for review, XenoPort ($XNPT) announced that it had revised its development pact with GSK on the new therapy for restless leg syndrome. XenoPort retrieved ex-U.S. rights to the therapy, while leaving GSK in charge of the U.S. market. In a statement the developer also said that the two partners had revised the terms of the deal, but no numbers were outlined. The FDA had rejected Horizant after noting signs of cancer in a rat study. XenoPort release

Suggested Articles

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.

The appointments are part of Verona’s efforts to prepare for phase 3 development of ensifentrine in chronic obstructive pulmonary disease.